Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer

Prostate Cancer and Prostatic Diseases volume 24, pages 61–68 (2021)Cite this article

Subjects

Abstract

Purpose

Monoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer.

Materials and methods

An open-label single arm clinical trial enrolled subjects with biochemical recurrent prostate cancer defined by PSA ≥ 0.4 ng/ml (post prostatectomy) or PSA ≥ 2 ng/ml above nadir (post-radiation therapy); no evidence of metastasis on imaging; and normal androgen levels. Subjects received phenelzine 30 mg orally twice daily. Mood symptoms were assessed with the hospital anxiety depression score (HADS) questionnaire. The primary endpoint was the proportion of patients who achieved a PSA decline of ≥50% from baseline.

Results

Characteristics of the 20 eligible patients enrolled included: mean ± SD age 66.9 ± 4.8 years and PSA 4.7 ± 5.8 ng/dl. Maximal PSA declines ≥30% and ≥50% were observed in 25% (n = 5/20) and 10% (n = 2/20) of subjects, respectively. At 12 weeks, 17 subjects remained on treatment with PSA declines ≥30% and ≥50% of 24% (n = 4/17) and 6% (n = 1/17), respectively. Common toxicities observed included dizziness (grade 1 = 45%, grade 2 = 35%), hypertension (grade ≥ 2 = 30%), and edema (grade 1 = 25%, grade 2 = 10%). There was one episode of grade 4 hypertension (cycle 4) and two episodes of grade 3 syncope (cycle 12 and cycle 14) requiring treatment discontinuation. HADS questionnaires demonstrated a significant decrease in anxiety with no change in depressive symptoms on treatment.

Conclusions

Phenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Changes in PSA relative to phenelzine treatment.
Fig. 2: Longitudinal analysis of PSA levels over time in responding subjects.
Fig. 3: Changes in patient self-report of mood symptoms on treatment.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author upon request.

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

    PubMed  Google Scholar 

  2. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598–604.

    Article  CAS  PubMed  Google Scholar 

  3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910–4.

    Article  PubMed  Google Scholar 

  4. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology. 2000;55:323–7.

    Article  CAS  PubMed  Google Scholar 

  5. Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, et al. Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. Eur Urol. 2017;72:689–709.

    Article  PubMed  Google Scholar 

  6. Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA. Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am. 2013;27:1205–19.

    Article  PubMed  Google Scholar 

  7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–7.

    Article  CAS  PubMed  Google Scholar 

  8. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32–9.

    Article  CAS  PubMed  Google Scholar 

  9. Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018;19:76–86.

    Article  CAS  PubMed  Google Scholar 

  10. Ou XM, Chen K, Shih JC. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem. 2006;281:21512–25.

    Article  CAS  PubMed  Google Scholar 

  11. Zhao H, Nolley R, Chen Z, Reese SW, Peehl DM. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation. 2008;76:820–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA. 2006;103:10991–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Liao CP, Lin TP, Li PC, Geary LA, Chen K, Vaikari VP, et al. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene. 2018;37:5175–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gaur S, Gross ME, Liao CP, Qian B, Shih JC. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Prostate. 2019;79:667–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, et al. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest. 2014;124:2891–908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010;77:859–82.

    Article  PubMed  Google Scholar 

  17. Gillman PK, Feinberg SS, Fochtmann LJ. Revitalizing monoamine oxidase inhibitors: a call for action. CNS Spectr. 2019:1–3. https://doi.org/10.1017/S1092852919001196. PMID: 31272520.

  18. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973–8.

    Article  CAS  PubMed  Google Scholar 

  19. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.

    Article  PubMed  Google Scholar 

  20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.

    Article  CAS  PubMed  Google Scholar 

  21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.

    Article  CAS  PubMed  Google Scholar 

  22. Parke-Davis DoPI. Nardil (Phenelzine Sulfate) package insert. New York, NY 10017.

  23. Mitchell AJ, Meader N, Symonds P. Diagnostic validity of the hospital anxiety and depression scale (HADS) in cancer and palliative settings: a meta-analysis. J Affect Disord. 2010;126:335–48.

    Article  PubMed  Google Scholar 

  24. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295–309.

    Article  CAS  PubMed  Google Scholar 

  25. Birkenhäger TK, van den Broek WW, Mulder PG, Bruijn JA, Moleman P. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry. 2004;65:1505–10.

    Article  PubMed  Google Scholar 

  26. Lofters A, Juffs HG, Pond GR, Tannock IF. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. J Urol. 2002;168:2516–20.

    Article  PubMed  Google Scholar 

  27. Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005;104:467–78.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Presented in part at the Prostate Cancer Foundation Annual Scientific Retreat October 2016. We thank Mayada Aljehani for statistical analysis and the nurses and research staff at the Ellison Institute for Transformative Medicine of USC, LAC + USC Medical Center and the USC Norris Comprehensive Cancer Center who contributed to this trial.

Funding

USC-Taiwan Center for Translational Research supported by Tsai Family Fund to Jean C. Shih. This work was partially supported by National Cancer Institute Cancer Center Shared Grant award P30CA014089. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. None of the funding sources influenced the design, analysis, or conclusions of the study.

Author information

Authors and Affiliations

  1. Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA

    Mitchell E. Gross, David B. Agus, Olga Castellanos & Patrick Gilmore

  2. Department of Medicine, University of Southern California, Los Angeles, CA, USA

    Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek K. Pinski & David I. Quinn

  3. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek K. Pinski, David I. Quinn & Jean C. Shih

  4. Department of Integrative Anatomical Sciences, University of Southern California, Los Angeles, CA, USA

    Jean C. Shih

  5. Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA

    Jean C. Shih

Authors
  1. Mitchell E. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David B. Agus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tanya B. Dorff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacek K. Pinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David I. Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Olga Castellanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patrick Gilmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean C. Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MEG and JCS were responsible for trial conception and design. MEG, DBA, TD, JP, and DQ were involved in study conduct including patient enrollment, treatment, and data collection. MEG, OC, and PG assembled the data. MEG analyzed the data and drafted the report. All authors critically reviewed the manuscript and approved the final manuscript.

Corresponding authors

Correspondence to Mitchell E. Gross or Jean C. Shih.

Ethics declarations

Ethics approval and consent to participate

The clinical research protocol was approved by the Institutional Review Board (IRB) at the University of Southern California (USC), Los Angeles, California. All patients gave prospective consent to participate in all study procedures.

Conflict of interest

MEG serves as a consultant for Amgen and BeiGene and receives institutional research funding from Clovis Oncology, Glaxo-Smith-Kline, and BeiGene. TBD serves as a consultant for Bayer, Noxopharm, Roche, and Seattle Genetics, is a speaker for Exelixis, and receives institutional research funding from Bayer. DIQ serves as a consultant for Astellas, AstraZeneca, Bayer, Genzyme-Sanofi, Jannsen, Clovis and Pfizer. JCS has a patent entitled Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer. US Patent No. 9.771,625. The other authors declare no conflicts of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gross, M.E., Agus, D.B., Dorff, T.B. et al. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis 24, 61–68 (2021). https://doi.org/10.1038/s41391-020-0211-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-020-0211-9

This article is cited by

Search

Advanced search

Quick links